GeneDx Holdings Corp

GeneDx Holdings Corp. is a patient centered health intelligence company. It engages in transforming healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and genomic data to build dynamic models of human health and defining optimal, individualized health trajectories. The firm, through its Centrellis health intelligence platform, generates a more complete understanding of disease and wellness and provides science-driven solutions to the most pressing medical needs. The company was founded by Eric Schadt in October 2015 and is headquartered in Stamford, CT.

Earnings data Q1 2024

GeneDx reports robust Q1 2023 performance and outlines growth strategies

GeneDx reports strong Q1 2023 performance, driven by increased volume and revenue, with a focus on rare disease testing and whole exome sequencing. The company aims to capitalize on growth opportunities while addressing challenges related to cash burn and gross margin improvement.

GeneDx achieves record-breaking growth, focuses on sustainable profitability

GeneDx's Q2 2023 performance reflects strong growth in test volume and revenue, driven by a strategic focus on sustainable growth and profitability. The company's commitment to genetic research, commercial strategy, and cooperative efforts with patient advocacy organizations position it for future success. However, challenges in achieving profitability by 2025 and ongoing efforts to improve cost management and pricing present areas of focus. Despite challenges, opportunities for revenue and margin expansion through improved gross margins and ASP growth are evident.

GeneDx reports strong Q3 performance, focuses on exome growth

GeneDx's Q3 2023 performance reflects positive growth trends, with strong revenue, improved gross margin, and reduced operating expenses. The company's strategic strengths lie in its focus on exome and genome growth, cost reduction efforts, and balance sheet fortification. However, challenges in achieving sustainable profitability and navigating cost efficiency exist, while opportunities in increasing clinician orders and revenue enhancement through reduced denial rates and efficient operations are present.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The Company will also participate in a World Orphan Drug Congress panel presentation highlighting the role of genomic sequencing in advancing precision medicine The Company will also participate in a World Orphan Drug Congress panel presentation highlighting the role of genomic sequencing in advancing precision medicine

GeneDx Announces Partnership with Komodo Health to Expand Access to World's Largest Rare Disease Dataset

Management will host a conference call on Monday, April 29, 2024 to discuss first quarter 2024 financial and operating results at 4:30 p.m. Eastern Time.

GeneDx to Report First Quarter 2024 Financial Results on Monday, April 29, 2024

GENEDX HOLDINGS (WGS) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Here's Why GENEDX HOLDINGS (WGS) Could be Great Choice for a Bottom Fisher

STAMFORD, Conn., March 14, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced its scientific contributions at the 2024 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting. Across one platform presentation, an industry symposium and six poster presentations, including one selected as a “Rapid Fire Poster Session,” an invitation-only presentation of the top 20 ACMG posters, GeneDx continues to demonstrate its industry leadership in shaping the future landscape of genomics.

GeneDx to Present Data at the 2024 American College of Medical Genetics (ACMG) Annual Meeting Demonstrating Clinical Superiority of its Exome, Paving the Way for the Future of Genomics

STAMFORD, Conn., Feb. 26, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced that company management will participate in the Cowen Healthcare Conference from March 4-6 in Boston, MA.

GeneDx to Participate in 44th Annual Cowen Health Care Conference

GeneDx Holdings Corp. (WGS) Q4 2023 Earnings Call Transcript

Reported fourth quarter 2023 revenue from continuing operations 1 of $58.1M with more than 68% year-over-year growth of exome and genome test revenue Expanded fourth quarter 2023 adjusted gross margins 2 from continuing operations to 56% Narrowed fourth quarter 2023 adjusted net loss 2 to $17.8M and delivered 51% year-over-year cash burn reduction Issued guidance to deliver between $220M and $230M in FY 2024 revenue and reiterate path to profitability in 2025 GeneDx to host conference call today at 4:30 p.m. ET STAMFORD, Conn.

GeneDx Reports Fourth Quarter and Full Year 2023 Financial Results and Issues Guidance for Full Year 2024

GeneDx management will host a conference call at 4:30 p.m. Eastern Time on February 20, 2024 to discuss 2023 results and share full year 2024 guidance.

GeneDx to Report Fourth Quarter 2023 Financial Results on Tuesday, February 20, 2024

STAMFORD, Conn., Jan. 24, 2024 (GLOBE NEWSWIRE) -- GeneDx, a leader in delivering improved health outcomes through genomic and clinical insights, today announced that, effective as of January 23, 2024, the compensation committee of GeneDx's board of directors granted newly hired employees 106,030 restricted stock units (“RSUs”) as inducements material to each employee entering into employment with GeneDx. The RSUs were granted under GeneDx's 2023 Equity Inducement Plan and in accordance with Nasdaq Listing Rule 5635(c)(4).

GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GeneDx Holdings Corp shares jumped 21% to $4.68 in late-morning trading on Tuesday after the provider of exome and genome testing and interpretation announced that it expects to exceed revised 2023 revenue guidance with fourth quarter 2023 revenue from continuing operations of more than $57 million.   GeneDx also said it expects at least 63% year-over-year growth from its exome and genome test revenue.

GeneDx Holdings stock climbs on upbeat 4Q guidance, profitability target

Expects to exceed revised 2023 revenue guidance with fourth quarter 2023 revenue from continuing operations1 of more than $57M with at least 63% year-over-year revenue growth for exome and genome test revenue Reduced fourth quarter 2023 cash burn 51% year-over-year and 21% sequentially Ending December 31, 2023 cash position of at least $131 million Reiterating the path to profitability in 2025 STAMFORD, Conn., Jan. 08, 2024 (GLOBE NEWSWIRE) -- GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today reported preliminary financial results for the fourth quarter and full year of 2023.

GeneDx Announces Preliminary 2023 Financial Results

New research from one of the largest exome sequencing studies of patients with epilepsy adds to the mounting evidence that exome sequencing offers superior clinical results compared to multi-gene panels New research from one of the largest exome sequencing studies of patients with epilepsy adds to the mounting evidence that exome sequencing offers superior clinical results compared to multi-gene panels

GeneDx Presents New Data at the American Epilepsy Society Annual Meeting Demonstrating That Exome Sequencing Outperforms Multi-Gene Panels for Patients with Epilepsy

STAMFORD, Conn., Nov. 28, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced that company management will participate in the Evercore ISI HealthCONx Conference this week in Miami, FL.

GeneDx to Participate in 6th Annual Evercore ISI HealthCONx Conference

After losing some value lately, a hammer chart pattern has been formed for GeneDx Holdings Corp. (WGS), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Bears are Losing Control Over GeneDx Holdings Corp. (WGS), Here's Why It's a 'Buy' Now

GeneDx Holdings Corp. (NASDAQ:WGS ) Q3 2023 Results Conference Call October 30, 2023 4:30 PM ET Company Participants Sabrina Dunbar - Chief of Staff Katherine Stueland - President and CEO Kevin Feeley - CFO Conference Call Participants Joe Flanagan - Cowen Mark Massaro - BTIG Matt Kim - Jefferies Prashant Kota - Goldman Sachs Operator Good day, and thank you for standing by. Welcome to the GeneDx Third Quarter 2023 Earnings Conference Call.

GeneDx Holdings Corp. (WGS) Q3 2023 Earnings Call Transcript

Reported total revenue of $53M with more than 40% year-over-year growth of exome and genome test revenue

GeneDx Reports Third Quarter 2023 Financial Results and Business Highlights

STAMFORD, Conn., Oct. 09, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced it will release financial results for the third quarter of 2023 after the market closes on Monday, October 30, 2023. On the same day, Katherine Stueland, President and Chief Executive Officer of GeneDx, and Kevin Feeley, Chief Financial Officer of GeneDx, will host a conference call to discuss financial and operating results at 4:30 p.m. Eastern Time.

GeneDx to Report Third Quarter 2023 Financial Results on Monday, October 30, 2023

STAMFORD, Conn., Aug. 21, 2023 (GLOBE NEWSWIRE) -- GeneDx, a leader in delivering improved health outcomes through genomic and clinical insights, today announced that Genetics in Medicine, the official journal of the American College of Medical Genetics and Genomics (ACMG) has published a peer-reviewed research analysis resulting from a multi-lab collaboration involving GeneDx. The study, “The landscape of reported VUS in multi-gene panel and genomic testing: Time for a change,” evaluated the rate of inconclusive genetic variants, or variants of uncertain significance (VUS), reported with multi-gene panels versus exome and genome sequencing. Study findings concluded that VUS are reported more frequently on multi-gene panels (32.6%) than exome and genome sequencing (22.5%).

GeneDx Announces Data Demonstrating that Whole Exome and Genome Sequencing Report Fewer Variants of Uncertain Significance (VUS) than Multi-Gene Panel Testing Published in Genetics in Medicine

GeneDx Holdings Corp. (NASDAQ:WGS ) Q2 2023 Results Conference Call August 8, 2023 4:30 PM ET Company Participants Tricia Truehart - Head, IR Katherine Stueland - President and CEO Kevin Feeley - CFO Conference Call Participants Mark Massaro - BTIG Matt Kim - Jefferies Prashant Kota - Goldman Sachs Dan Brennan - Cowen Operator Good day, and thank you for standing by. Welcome to the GeneDx Second Quarter 2023 Earnings Conference Call.

GeneDx Holdings Corp. (WGS) Q2 2023 Earnings Call Transcript

Pacific Biosciences of California

Study is first of its kind to compare diagnostic rates across short- and long-read sequencing platforms  MENLO PARK, Calif. and STAMFORD, Conn.

PacBio and GeneDx Launch Research Collaboration with the University of Washington to Study Long-Read Whole Genome Sequencing for Increased Diagnostic Yield in Neonatal Care

Partnership allows commercial biopharma companies to leverage real-time data within comprehensive Prognos Marketplace to provide available treatment options for patients Partnership allows commercial biopharma companies to leverage real-time data within comprehensive Prognos Marketplace to provide available treatment options for patients

GeneDx and Prognos Health Announce Strategic Partnership to Help Rare Disease Patients More Rapidly Gain Access to Potential Treatment Options

STAMFORD, Conn., July 18, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced it will release financial results for the second quarter of 2023 after the market closes on Tuesday, August 8, 2023. On the same day, the management team from GeneDx will host a conference call to discuss financial and operating results at 4:30 p.m. Eastern Time.

GeneDx to Report Second Quarter 2023 Financial Results on Tuesday, August 8, 2023

STAMFORD, Conn., June 28, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced it will present new data on urine mitochondrial DNA testing at the 2023 United Mitochondrial Disease Foundation's (UMDF) Mitochondrial Medicine Symposium in Charlotte, North Carolina, June 28 - July 1, 2023.

GeneDx to Present New Data on Urine Mitochondrial DNA Testing at the 2023 United Mitochondrial Disease Foundation's Mitochondrial Medicine Symposium

N ew paper published today in Nature Methods describes the PanGenome Research-Tool Kit for analyz ing complex regions of the human pan genome

GeneDx Announces New Tool to Help Harness Human Pangenome Diversity for Clinical Interpretation of Variants

Eight state Medicaid programs now cover rWGS in the pediatric inpatient setting, with active bills in other states Eight state Medicaid programs now cover rWGS in the pediatric inpatient setting, with active bills in other states

News for GeneDx Holdings Corp Stock (WGS)